ムラヤマ ノリオ
Murayama Norio
村山 憲男 所属
人間社会学部 心理学科
生活機構研究科 心理学専攻
生活心理研究所 所属教員
生活機構研究科 生活機構学専攻
職種
准教授
|
|
言語種別 | 英語 |
発行・発表の年月 | 2009/06 |
形態種別 | 学術雑誌 |
査読 | 査読あり |
標題 | Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan |
執筆形態 | 共著 |
掲載誌名 | Psychogeriatrics |
掲載区分 | 国外 |
巻・号・頁 | 9,pp.50-55 |
著者・共著者 | Motohiro NOZAWA, Yousuke ICHIMIYA, Eiko NOZAWA, Yushi UTUMI, Hideki SUGIYAMA, Norio MURAYAMA, Eizo ISEKI, Heii ARAI |
概要 | Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer's disease.
Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer's disease. Cognitive function was evaluated using the Revised Hasegawa Dementia Scale and mini-mental state examination at the day before starting, and at 4, 8 and 24 weeks after starting donepezil 10 mg/day. The relationship with apolipoprotein E4 was also investigated. Results: The Revised Hasegawa Dementia Scale and mini-mental state examination scores were not statistically significantly different at any time after starting donepezil 10 mg/day. It can be anticipated that donepezil 10 mg/day will especially inhibit deterioration of cognitive function in advanced Alzheimer's disease. The incidence of adverse events was 11.5%, lower than the rate of 40% or higher recorded during previous clinical trials. Conclusions: The progression of cognitive dysfunction could be inhibited by increasing the dose of donepezil to 10 mg/day. It was suggested that longer-term treatment with 5 mg/day might lead to fewer adverse events when the dose is increased to 10 mg/day. |